HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 07, July 2018 – Water management- Technologies for biotech and pharmaceutical industries       » Why sunshine improves mood and makes us smarter       » SGD110 million lab to create healthier foods and sustainable biochemicals       » Entries open for the USD170,000 Ryman Prize       » Could the eye be the window to brain degeneration?       » High vitamin D levels linked to lower cholesterol in children      
INSIDE INDUSTRY
Ryzodeg reduces hypoglycaemia in type 2 diabetic fasting patients
Ryzodeg significantly reduces the risk of low blood sugar in people with type 2 diabetes who fast during Ramadan, by 62%

Millions of people with type 2 diabetes participate in Ramadan every year and we know that periods of prolonged fasting can increase the risk of hypoglycaemia," said lead investigator Dr Mohamed Hassanein of the Dubai Hospital, Dubai Health Authority, UAE and chair of the Diabetes and Ramadan International Alliance (DAR).

In people with type 2 diabetes who fast during Ramadan, Ryzodeg (insulin degludec and insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe episodes by 62% and the rate of nocturnal hypoglycaemia by 74% versus biphasic insulin aspart 30 (BIAsp 30 [NovoMix 30]).

It is estimated that worldwide over 116 million Muslims with diabetes may choose to fast during Ramadan. Muslims with type 2 diabetes who fast during Ramadan have up to a 7.5-fold increased risk of severe hypoglycaemia.

"This trial has shown that Ryzodeg is not only a simple treatment option which can make daily life easier for people with diabetes. Ryzodeg also reduces the risk of potentially dangerous episodes of hypoglycaemia in people with type 2 diabetes who choose to fast during Ramadan," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.

The Ramadan trial compared the efficacy and safety of Ryzodeg庐 twice daily and BIAsp 30 (NovoMix庐) twice daily in subjects with type 2 diabetes before, during and after Ramadan. The trial was a 28-week, international, open-label, randomised, treat-to-target trial involving 263 adults from five countries with large Muslim populations (Algeria, India, Lebanon, Malaysia and South Africa). The primary endpoint was change in HbA1c from baseline to the end of the month of Ramadan (four-week period). Secondary confirmatory endpoints included rates of blood sugar confirmed, nocturnal and severe hypoglycaemia.

Ryzodeg received its first regulatory approval in December 2012 and European Medicines Agency approval in January 2013. Since then, Ryzodeg has been approved in more than 70 countries, including the US in September 2015. It is now available in 13 countries.

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Click here to receive APBN e-newsletters once a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management- Technologies for biotech and pharmaceutical industries
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy